• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Prospective, multicenter, randomized, controlled trial evaluating the performance of a novel combination powder vs hemostatic matrix in cardiothoracic operations
ConclusionsIn this multicenter, randomized, controlled trial, comparison of CP to HM revealed CP superiority and noninferiority for TTTH at 3 and 5  minutes, respectively.
Source: Journal of Cardiac Surgery - November 24, 2019 Category: Cardiovascular & Thoracic Surgery Authors: Nicholas C. Dang, Abbas Ardehali, Brian A. Bruckner, Patrick E. Parrino, Daniel L. Gillen, Rachel W. Hoffman, Russell Spotnitz, Stephanie Cavoores, Ian J. Shorn, Roberto J. Manson, William D. Spotnitz Tags: ORIGINAL ARTICLE Source Type: research

Application techniques of a novel hemostat in cardiac operations: HEMOBLAST
ConclusionHB is a novel powder ‐based multiple component hemostatic agent that promotes focal or large area hemostasis. We have presented the techniques of use that are important to the successful application of HB to facilitate hemostasis.
Source: Journal of Cardiac Surgery - September 5, 2019 Category: Cardiovascular & Thoracic Surgery Authors: Brian A. Bruckner, Uy Ngo, Mahesh Ramchandani, Erik Suarez, Samir Awad, Michael Reardon Tags: SURGICAL TECHNIQUE Source Type: research

Hemostasis Solution Controls Bleeding during Surgery
A novel handheld device delivers a powder based on collagen to help surgeons achieve hemostatic bleeding control during surgical procedures.The Biom ’Up (Saint-Priest, France) HemoBlast Bellows is a sterile delivery device that is preloaded with a dry, sterile powder made of highly purified porcine collagen, glucose, chondroitin sulfate, and thrombin. The hemostatic powder is applied to the source of the bleeding by squeezing the bellows. Once applied, the powdered collagen and glucose components start the coagulation process by absorbing blood, concentrating coagulation factors and platelets, and providing a surface for...
Source: Medical Hemostat - January 2, 2018 Category: Medical Devices Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs

Cost effectiveness analysis of sealing hemostat patches vs. standard of care in cardiac surgery.
CONCLUSIONS: This analysis supports the use of HEMOPATCH over SOC in cardiac surgery in European hospitals to improve hemostasis success rates and potential cost offsets from reduced transfusions, complications, and surgical revisions. PMID: 29096598 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - November 5, 2017 Category: Health Management Tags: J Med Econ Source Type: research

Gecko Biomedical receives CE Mark Approval for SETALUM ™ Sealant
Paris, France, September 11, 2017 – Gecko Biomedical (“Gecko”), a medical device company developing innovative polymers to support tissue reconstruction, announced today that it has received CE Mark approval for its SETALUM™ Sealant allowing the company to market its technology in Europe.The SETALUM ™ Sealant is a biocompatible, bioresorbable and on-demand activated sealant usable in wet and dynamic environments as an add-on to sutures during vascular surgery. The polymer is applied to tissue in-situ and activated using a proprietary light activation pen.The technology at the foundation of the SETALUM ™ Sealant...
Source: Medical Hemostat - October 25, 2017 Category: Medical Devices Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs